Investigation of Metformin effectiveness among Pre-diabetics on CVDs event reduction: A multi centric Clinical Trial


This study is a multi-center, prospective, randomized, double-blind, parallel design trial comparing the effect of Metformin versus placebo on a macro vascular composite outcome and diabetes incidence in people in primary care with non-diabetic hyperglycemia (NDH) (100≤FPG<126) and at high cardiovascular risk (at least 10-year CVD risk ≥12% according to Framingham risk scoring/ QRISK2). Participants will be allocated randomly to be treated with either Metformin versus placebo plus life style modification if high risk for cardiovascular diseases, and will be followed for about 7 years. The purpose of clinical trial is to establish the effectiveness and cost effectiveness of Metformin in preventing cardiovascular events over seven years in people with non-diabetic hyperglycemia at high cardiovascular risk



Contact Info

  • Non-Communicable Diseases Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences

    No. 10, Al-e-Ahmad and Chamran Highway intersection, Tehran

    Postcode: 1411713136

  • +9821-88631293
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

Viewer's statistics

This week1191
This month5043

Who Is Online


Contact Us

ReCaptcha plugin is missing. Please install this plugin before!